Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Sulfate for Prevention of POAF
NCT05669417Phase 3Terminated
- Sponsor
- HagaZiekenhuis
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of magnesium sulfate in Atrial fibrillation (AFib) (2 arms), sponsored by HagaZiekenhuis. Primary endpoint: Incidence of new-onset postoperative atrial fibrillation at 7 days. Started Aug 2022; status: terminated.
02
Drugs
magnesium sulfate
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05669417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669417.